New England Biolabs Inc v F. Hoffman-La Roche AG

New England Biolabs Inc (NEB) and F. Hoffman-La Roche AG (Roche) were parties to proceedings in the High Court of Australia concerning the validity of certain patent claims. The dispute centred on NEB's allegations that Roche had infringed its Australian patent, which related to a method for producing a specific enzyme, deoxyribonucleic acid polymerase (DNA polymerase). Roche, in turn, sought to have NEB's patent declared invalid.

The High Court was required to determine, among other things, whether the patent claims were valid and, if so, whether Roche's activities constituted an infringement of those claims. Specifically, the court had to consider whether the patent met the requirements of novelty and inventive step under the *Patents Act 1990* (Cth), and whether the patent adequately disclosed the invention to enable a person skilled in the art to perform it. The question of infringement also involved an assessment of whether Roche's product fell within the scope of the patent claims.

In its reasoning, the High Court applied established principles of patent law, including the tests for novelty and inventive step. The court examined the prior art to determine if the invention as claimed was already known or obvious. It also considered the sufficiency of the patent specification, assessing whether it provided a clear and complete description of the invention. The court's analysis of infringement involved a purposive construction of the patent claims, considering the substance of the invention rather than a literal interpretation of the wording. The court ultimately found that certain claims of the patent were invalid for want of novelty and inventive step, and that Roche had not infringed the valid claims.